Rodgers P A, Seidman D S, Wei P L, Dennery P A, Stevenson D K
Department of Pediatrics, Stanford University School of Medicine, California 94304-0126, USA.
Pediatr Res. 1996 Jun;39(6):1041-9. doi: 10.1203/00006450-199606000-00018.
Zinc protoporphyrin IX (ZnPP) has been shown to inhibit heme oxygenase (HO) activity effectively in vivo and has potential in the treatment of neonatal jaundice. Because this is a transitional or temporary condition lasting only several days, an effective chemopreventive agent with a relatively short duration of action would be desirable for the treatment of severe neonatal jaundice. To determine the effective duration of action of ZnPP, we administered either 40 nmol/g of body weight ZnPP or 5 microL/g body weight diluent intraperitoneally to neonatal rats 24-36 h after birth. Between 0 and 21 d after ZnPP dosing, the duration of action was investigated through measurements of serum bilirubin and hepatic and splenic HO inhibition, which were correlated to measurements of ZnPP distribution. Significant (p < 0.05) hepatic HO inhibition, ranging from 27 to 51%, was observed in the liver between 1 and 4 d after dosing, concurrent with a 23-28% reduction in serum bilirubin levels, and was associated with ZnPP tissue concentrations of 27-38 nmol/g. Splenic HO was not inhibited measurably by the much lower concentrations of ZnPP found in the spleen (2.8-20.1 nmol/g) between 0 and 21 d after dosing. Furthermore, HO isoform 1 (HO-1) induction was apparently not a confounding factor in the duration of action of ZnPP, because the modest increases in HO-1 protein levels were not sustained longer than 24 h after ZnPP administration. Our findings demonstrated that the duration of action of ZnPP in neonatal rats is less than 1 wk. The reduction in serum bilirubin levels, the short duration of action and minimal confounding effects suggest that ZnPP may be an effective chemopreventive agent for the treatment of severe neonatal jaundice.
锌原卟啉IX(ZnPP)已被证明在体内能有效抑制血红素加氧酶(HO)的活性,并且在新生儿黄疸的治疗中具有潜力。由于这是一种仅持续数天的过渡性或暂时性病症,因此对于严重新生儿黄疸的治疗,需要一种作用持续时间相对较短的有效化学预防剂。为了确定ZnPP的有效作用持续时间,我们在新生大鼠出生后24 - 36小时经腹腔给予40 nmol/g体重的ZnPP或5 μL/g体重的稀释剂。在给予ZnPP后的0至21天之间,通过测量血清胆红素以及肝脏和脾脏中HO的抑制情况来研究作用持续时间,这些测量结果与ZnPP的分布测量相关。给药后1至4天,在肝脏中观察到显著(p < 0.05)的肝脏HO抑制,范围为27%至51%,同时血清胆红素水平降低23% - 28%,并且这与ZnPP在组织中的浓度为27 - 38 nmol/g相关。在给药后0至21天之间,脾脏中ZnPP的浓度要低得多(2.8 - 20.1 nmol/g),未观察到脾脏HO受到可测量的抑制。此外,HO同工酶1(HO - 1)的诱导显然不是ZnPP作用持续时间的混杂因素,因为在给予ZnPP后,HO - 1蛋白水平的适度升高持续时间不超过24小时。我们的研究结果表明,ZnPP在新生大鼠中的作用持续时间小于1周。血清胆红素水平的降低、作用持续时间短以及最小的混杂效应表明,ZnPP可能是治疗严重新生儿黄疸的一种有效化学预防剂。